Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
COMPANY
In Conversation: Dr. Amrie Grammer, Co-founder, President and Chief Scientific Officer, AMPEL Biosolutions
These are exciting times for the AMPEL team. BioBuzz thought it was a great time to catch up with AMPEL’s Co-founder, President, and Chief Scientific Officer Dr. Amrie Grammer to discuss her founder’s journey and AMPEL’s promising future.
Personalized Precision Medicine (Audio)
Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.
Eight Innovative, Virginia Life Science Startups to Know
There are a host of exciting, innovative startup companies that call Charlottesville home. We’re excited to highlight these nine innovative Charlottesville, Virginia startup companies and look forward to telling their stories well into the future.
Trial of LuPRO mobile app predicts Lupus flares
CLICK TO VIEW ORIGINAL ARTICLE > BY KATIE O'CONNOR, Richmond Times-Dispatch In 50 years, only one treatment was approved by the U.S. Food and Drug Administration to treat lupus, an autoimmune disease in which a person’s immune system attacks their healthy organs...
Dr. Amrie Grammer of AMPEL BioSolutions joins host Rich Bendis on BioTalk
CLICK TO VIEW ARTICLE & WATCH VIDEO > AMPEL BioSolutions Co-Founder and COO/CSO, Dr. Amrie Grammer guests on BioTalk to discuss building the Company in Charlottesville, VA, her work and recognition at NIH, and being a leader from the southern part of the...
Cville Company Uses Genetics and Big Data to Find Better Medical Treatments
CLICK TO READ AND LISTEN TO ARTICLE > Getting approval for new drugs takes years and costs companies millions of dollars. What’s more, clinical trials sometimes fail, leaving firms with nothing to show. Now, however, a Virginia company is taking a different...
PLATFORM
Bloomberg’s “The Tape” Personalized Precision Medicine (Audio)
Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer.
MI/AL for Diagnosis & Prognosis
Presentation by Amrie Grammer, Ph.D, COO/CSO, AMPEL BioSolutions at the Precision Medicine World Conference on June 28, 2022
PRODUCTS
This New Blood Test For Fibromyalgia Could Identify Your Best Treatment Options
Different from the FM/a blood test used for diagnosis, this new blood test for Fibromyalgia may be the key to your treatment plan.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO READ ARTICLE > AMPEL BioSolutions announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is irreversible and providing decision support for prophylactic...
New test to identify, treat kidney disease
CLICK TO READ ARTICLE & VIEW VIDEO > By Felicity Taylor CHARLOTTESVILLE, Va. (CBS19 NEWS) -- A local company says it has discovered a new way to identify and treat kidney disease. AMPEL BioSolutions is a precision medicine company that studies RNA and gene...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ -- AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ -- AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ORIGINAL ARTICLE > CHARLOTTESVILLE, Va., February 28, 2023 -- AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is...
PARTNERS
Reuters – Google Webinar Featuring AMPEL for Pharma Partnering
Reuters Events webinar with AMPEL, Google Cloud, Novartis, Asklepios and Pfizer to learn how data-driven innovation is reshaping clinical trials and paving the way towards faster drug discovery, more diverse patient enrolment and improved patient retention.
AMPEL’s AL/ML in Clinical Trial Design
Panel Presentation at the Precision Medical World Conference, June 29, 2022
Podcast on Lupus Diagnosis & Treatment
An Interview with Dr. Amrie Grammer on Dartmouth's "No Scrubs" Podcast